[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.247.205. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 405
Citations 0
Health Agencies Update
May 28, 2014

FDA Approves First Sublingual Therapies for Allergic Rhinitis

JAMA. 2014;311(20):2057. doi:10.1001/jama.2014.5757

The US Food and Drug Administration (FDA) approved the first sublingual allergen extract for treatment of allergic rhinitis, in this case for symptoms induced by exposure to grass pollen, on April 2 (http://1.usa.gov/1mKpSNe).

A growing body of evidence has suggested that desensitizing patients with allergies by sublingual exposure to tiny amounts of allergen may be effective. The new product, Oralair, consists of freeze-dried extracts of pollen from 5 common grasses (Kentucky bluegrass, orchard, perennial rye, sweet vernal, and Timothy).

First Page Preview View Large
First page PDF preview
First page PDF preview
×